Ga 68 PSMA-11

Generic Name
Ga 68 PSMA-11
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C44H59GaN6O17
CAS Number
1906894-20-9
Unique Ingredient Identifier
ZJ0EKR6M10
Background

Gallium (Ga) 68 prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and assess prostate-specific membrane antigen (PSMA)-positive lesions in adult men with prostate cancer during positron emission tomography (PET). Prostate cancer is one of the most commonly diagnosed cancers among men in Western...

Indication

Gallium Ga-68 gozetotide, or Gallium Ga-68 PSMA-11, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer metastasis with:

Associated Conditions
Prostate-specific Membrane Antigen Positive Tumors
Associated Therapies
-
Clinical Trials
Related News

68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer

Early Phase 1
Recruiting
Conditions
Prostate Cancer
Positron-Emission Tomography
Interventions
Drug: 68Ga-PSMA-11
First Posted Date
2021-04-05
Last Posted Date
2023-09-21
Lead Sponsor
First Affiliated Hospital of Fujian Medical University
Target Recruit Count
600
Registration Number
NCT04831541
Locations
🇨🇳

Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Phase 3
Active, not recruiting
Conditions
Prostatic Neoplasms
Interventions
Drug: 177Lu-PSMA-617
Drug: 68Ga-PSMA-11
Drug: ARDT
Drug: ADT
First Posted Date
2021-01-22
Last Posted Date
2024-12-20
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
1148
Registration Number
NCT04720157
Locations
🇺🇸

Mayo Clinic - Arizona Mayo Clinic Hospital, Scottsdale, Arizona, United States

🇺🇸

University of California San Diego - Moores Cancer Center, La Jolla, California, United States

🇺🇸

VA Greater LA Healthcare System, Los Angeles, California, United States

and more 65 locations

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

First Posted Date
2021-01-20
Last Posted Date
2024-10-16
Lead Sponsor
Thomas Hope
Target Recruit Count
15
Registration Number
NCT04716725
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

First Posted Date
2020-12-30
Last Posted Date
2024-08-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
469
Registration Number
NCT04689828
Locations
🇺🇸

Beth Israel Deaconess Med Ctr Dept. of BIDMC, Boston, Massachusetts, United States

🇺🇸

Uni of TX MD Anderson Cancer Cntr, Houston, Texas, United States

🇺🇸

Univ of Florida College of Medicine x, Gainesville, Florida, United States

and more 18 locations

[68Ga]Ga-PSMA-11 PET/CT in the Assessment of High Risk and Recurrent Prostate Cancer

Active, not recruiting
Conditions
Prostatic Neoplasm
Prostatic Cancer
Interventions
Drug: 68Ga-PSMA-11
First Posted Date
2020-07-23
Last Posted Date
2024-11-06
Lead Sponsor
British Columbia Cancer Agency
Target Recruit Count
1574
Registration Number
NCT04484701
Locations
🇨🇦

BC Cancer, Vancouver, British Columbia, Canada

A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

First Posted Date
2019-01-30
Last Posted Date
2024-03-21
Lead Sponsor
Cancer Targeted Technology
Target Recruit Count
17
Registration Number
NCT03822871
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

First Posted Date
2019-01-18
Last Posted Date
2024-01-11
Lead Sponsor
Andrei Iagaru
Target Recruit Count
14
Registration Number
NCT03809078
Locations
🇺🇸

Stanford University, Stanford, California, United States

PSMA Imaging of Localized Prostate Cancer

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: 89ZR-DF-IAB2M
Drug: 68Ga-PSMA-HBED-CC
First Posted Date
2018-09-18
Last Posted Date
2020-10-14
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
20
Registration Number
NCT03675451
Locations
🇺🇸

Weill Cornell Medicine, New York, New York, United States

177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC

First Posted Date
2018-06-04
Last Posted Date
2021-08-24
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
6
Registration Number
NCT03545165
Locations
🇺🇸

Weill Cornell Medical College, New York, New York, United States

Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC

Phase 1
Active, not recruiting
Conditions
Prostate Cancer
Interventions
Drug: 177Lu-PSMA-617
Drug: 68Ga-PSMA-HBED-CC
First Posted Date
2017-02-03
Last Posted Date
2023-11-02
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
50
Registration Number
NCT03042468
Locations
🇺🇸

Weill Cornell Medical College, New York, New York, United States

🇺🇸

Tulane Cancer Center Clinic, New Orleans, Louisiana, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy